{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:58Z","timestamp":1787020738495,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7252240"],"award-info":[{"award-number":["7252240"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2023-JYB-KYPT-17"],"award-info":[{"award-number":["2023-JYB-KYPT-17"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evodiamine (EVO) exerts promising therapeutic potential in the treatment of Ulcerative Colitis (UC). However, its clinical application is constrained by concerns regarding potential hepatotoxicity. A comprehensive understanding of underlying both the therapeutic effects and hepatotoxicity of EVO is therefore essential to enhance its safe and effective application in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to elucidate the regulatory mechanisms of gut-liver axis homeostasis in EVO-induced hepatotoxicity and its therapeutic effects on UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An integrated experimental strategy employing cell, zebrafish, and murine was implemented to assess the hepatotoxic effects of EVO. Transcriptomic and metabolomic analyses were performed in vitro, while targeted investigations of bile acids (BAs) metabolism were conducted in vivo to understand the overall response profile and the underlying mechanisms associated with EVO-induced hepatotoxicity. Furthermore, the expression patterns of proteins along the gut-liver axis were systematically evaluated under diverse physiological conditions to identify the potential interactions contributing to the alleviative effects of UC on EVO-induced hepatotoxicity and as well as to explore the therapeutic potential of EVO in UC management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High-dose EVO treatment was associated with notable hepatotoxic effects in both in vitro cellular models and normal in vivo animals, primarily manifested through disturbances in BAs metabolism, inflammatory responses, and apoptosis. In contrast, in UC models, EVO administration not only effectively ameliorated intestinal structural damage and functional impairments, but also demonstrated minimal hepatotoxicity. Mechanism studies documented that EVO disrupted bile acid metabolism by interfering with BSEP\/MRP2\/CYP7A1\/CYP27A1 pathways, while simultaneously triggering inflammation and apoptosis through PPAR\/NF-\u03baB\/ZO-1\/caspase-3 pathway, ultimately contributing to hepatotoxicity in healthy subjects. However, in the context of UC, the disease condition attenuated EVO-induced alterations in hepatic protein expression, thereby reducing its hepatotoxic potential. Meanwhile, under UC conditions, EVO restored the expression levels of relevant proteins in the intestinal tract, thereby maintaining its therapeutic efficacy against UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The hepatotoxicity observed under healthy conditions and the therapeutic efficacy of EVO against UC are both associated with EVO's modulation of the PPAR\/NF-\u03baB\/ZO-1\/caspase-3 pathway. The influence of EVO on the expression of these key proteins within the gut-liver axis may be modulated by distinct physiological states, resulting in either antagonistic or synergistic effects that potentially lead to differential biological responses across multiple organs. This study not only provides essential supplementation and refinement to the understanding of EVO-induced hepatotoxicity but also identifies a novel breakthrough in accurately assessing its liver toxicity. Specifically, the evaluation of EVO's hepatotoxic potential should be grounded in the principles of TCM and aligned with its clinical application characteristics. Furthermore, these findings offer valuable insights for the safety assessment and development of traditional Chinese medicines with potential hepatotoxic risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-025-01262-3","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:02:15Z","timestamp":1763683335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The conversion of evodiamine-induced hepatotoxicity into a therapeutic effect on colonitis: insight from the liver-gut axis mediated by PPAR\/NF-\u03baB\/ZO-1\/caspase-3 pathway"],"prefix":"10.1186","volume":"20","author":[{"given":"Chongjun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqi","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaimei","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"10","key":"1262_CR1","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2024.08.003","volume":"45","author":"P Wangchuk","year":"2024","unstructured":"Wangchuk P, Yeshi K, Loukas A. Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments. Trends Pharmacol Sci. 2024;45(10):892\u2013903.","journal-title":"Trends Pharmacol Sci"},{"key":"1262_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156539","volume":"139","author":"Y Liu","year":"2025","unstructured":"Liu Y, Zhang JT, Sun M, Song J, Sun HM, Wang MY, et al. Targeting ferroptosis in the treatment of ulcerative colitis by traditional Chinese medicine: a novel therapeutic strategies. Phytomedicine. 2025;139:156539.","journal-title":"Phytomedicine"},{"key":"1262_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jenvman.2024.122605","volume":"370","author":"T Yu","year":"2024","unstructured":"Yu T, Deng X, Yang X, Yin Y, Liu Y, Xu S. New insights into evodiamine attenuates IPEC-J2 cells pyroptosis induced by T-2 toxin - Activating Keap1-Nrf2\/NF-\u03baB signaling pathway through binding with Keap1. J Environ Manage. 2024;370:122605.","journal-title":"J Environ Manage"},{"key":"1262_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2024.116448","volume":"279","author":"Q Fan","year":"2024","unstructured":"Fan Q, Liang R, Chen M, Li Z, Tao X, Ren H, et al. Metabolic characteristics of evodiamine were associated with its hepatotoxicity via PPAR\/PI3K\/AKT\/NF-\u043aB\/tight junction pathway-mediated apoptosis in zebrafish. Ecotoxicol Environ Saf. 2024;279:116448.","journal-title":"Ecotoxicol Environ Saf"},{"key":"1262_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.115031","volume":"247","author":"Z Wang","year":"2023","unstructured":"Wang Z, Xiong Y, Peng Y, Zhang X, Li S, Peng Y, et al. Natural product evodiamine-inspired medicinal chemistry: anticancer activity, structural optimization and structure-activity relationship. Eur J Med Chem. 2023;247:115031.","journal-title":"Eur J Med Chem"},{"key":"1262_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.139597","volume":"300","author":"C Yang","year":"2025","unstructured":"Yang C, Wu X, Jiang Z, Ru Y, Shen B, Li F, et al. Evodiamine rescues lipopolysaccharide-induced cognitive impairment via C\/EBP-\u03b2-COX2 axis-regulated neuroinflammation. Int J Biol Macromol. 2025;300:139597.","journal-title":"Int J Biol Macromol"},{"key":"1262_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156251","volume":"135","author":"G Cui","year":"2024","unstructured":"Cui G, Wang M, Li X, Wang C, Shon K, Liu Z, et al. Berberine in combination with evodiamine ameliorates gastroesophageal reflux disease through TAS2R38\/TRPV1-mediated regulation of MAPK\/NF-\u03baB signaling pathways and macrophage polarization. Phytomedicine. 2024;135:156251.","journal-title":"Phytomedicine"},{"key":"1262_CR8","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2022.12704","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang Y, Zhao Y, Wu W, Meng W, Zhou Y, et al. Protection against ulcerative colitis and colorectal cancer by evodiamine via anti-inflammatory effects. Mol Med Rep. 2022. https:\/\/doi.org\/10.3892\/mmr.2022.12704.","journal-title":"Mol Med Rep"},{"key":"1262_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104978","volume":"159","author":"M-X Wang","year":"2020","unstructured":"Wang M-X, Lin L, Chen Y-D, Zhong Y-P, Lin Y-X, Li P, et al. Evodiamine has therapeutic efficacy in ulcerative colitis by increasing Lactobacillus acidophilus levels and acetate production. Pharmacol Res. 2020;159:104978.","journal-title":"Pharmacol Res"},{"key":"1262_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.573870","volume":"11","author":"W Ding","year":"2020","unstructured":"Ding W, Ding Z, Wang Y, Zhu Y, Gao Q, Cao W, et al. Evodiamine attenuates experimental colitis injury via activating autophagy and inhibiting NLRP3 inflammasome assembly. Front Pharmacol. 2020;11:573870.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1262_CR11","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/j.apsb.2024.03.002","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Gui Y, Rao J, Sun J, Wang G, Ren Q, et al. In silico off-target profiling for enhanced drug safety assessment. Acta Pharm Sin B. 2024;14(7):2927\u201341.","journal-title":"Acta Pharm Sin B"},{"key":"1262_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156433","volume":"138","author":"M Cui","year":"2025","unstructured":"Cui M, Zhang Y, Tang Y, Fan Q, Chen X, Li J, et al. Hepatotoxicity of Phytolacca acinosa Roxb mediated by phytolaccagenin via ferroptosis\/PPAR\/P53\/arachidonic acid metabolism. Phytomedicine. 2025;138:156433.","journal-title":"Phytomedicine"},{"key":"1262_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.119865","volume":"348","author":"Y Sheng","year":"2025","unstructured":"Sheng Y, Li X, Ye X, Fan Q, Li J, Qiao C, et al. Integrated transcriptomic and proteomic analysis of hepatotoxic effects of Venenum Bufonis in zebrafish. J Ethnopharmacol. 2025;348:119865.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"1262_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-022-00704-6","volume":"18","author":"L Chen","year":"2023","unstructured":"Chen L, Chen S, Sun P, Liu X, Zhan Z, Wang J. Psoralea corylifolia L.: a comprehensive review of its botany, traditional uses, phytochemistry, pharmacology, toxicology, quality control and pharmacokinetics. Chin Med. 2023;18(1):4.","journal-title":"Chin Med"},{"issue":"23","key":"1262_CR15","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1007\/s00216-023-04831-3","volume":"415","author":"T Peng","year":"2023","unstructured":"Peng T, Rao J, Zhang T, Wang Y, Li N, Gao Q, et al. Elucidation of the relationship between evodiamine-induced liver injury and CYP3A4-mediated metabolic activation by UPLC-MS\/MS analysis. Anal Bioanal Chem. 2023;415(23):5619\u201335.","journal-title":"Anal Bioanal Chem"},{"key":"1262_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22060943","author":"W Yang","year":"2017","unstructured":"Yang W, Ma L, Li S, Cui K, Lei L, Ye Z. Evaluation of the cardiotoxicity of Evodiamine in vitro and in vivo. Molecules. 2017. https:\/\/doi.org\/10.3390\/molecules22060943.","journal-title":"Molecules"},{"key":"1262_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2024.116563","author":"C-q Yang","year":"2024","unstructured":"Yang C-q, Lai C-c, Pan J-c, Gao J, Shen B-y, Ru Y, et al. Maintaining calcium homeostasis as a strategy to alleviate nephrotoxicity caused by evodiamine. Ecotoxicol Environ Saf. 2024. https:\/\/doi.org\/10.1016\/j.ecoenv.2024.116563.","journal-title":"Ecotoxicol Environ Saf"},{"key":"1262_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179955","author":"JY Eom","year":"2022","unstructured":"Eom JY, Choi SH, Kim HJ, Kim DH, Bae JH, Kwon GS, et al. Hemp-derived nanovesicles protect leaky gut and liver injury in Dextran sodium sulfate-induced colitis. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23179955.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1262_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/ecco-jcc\/jjad157","volume":"18","author":"A Beheshti Maal","year":"2024","unstructured":"Beheshti Maal A, Shahrbaf MA, Sadri B, Hossein-Khannazer N, Mansournia MA, Vosough M. Prevalence of hepatobiliary manifestations in inflammatory bowel disease: a GRADE assessed systematic review and meta-analysis of more than 1.7 million patients. J Crohns Colitis. 2024;18(3):360\u201374.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"1262_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/j.gastro.2024.02.026","volume":"167","author":"M Khrom","year":"2024","unstructured":"Khrom M, Long M, Dube S, Robbins L, Botwin GJ, Yang S, et al. Comprehensive association analyses of extraintestinal manifestations in inflammatory bowel disease. Gastroenterology. 2024;167(2):315\u201332.","journal-title":"Gastroenterology"},{"issue":"1","key":"1262_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","volume":"80","author":"KN van Munster","year":"2024","unstructured":"van Munster KN, Bergquist A, Ponsioen CY. Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two? J Hepatol. 2024;80(1):155\u201368.","journal-title":"J Hepatol"},{"key":"1262_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155851","volume":"132","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Zhou Y, Zhang Z, Zhao M, Hu C, Yang L, et al. Progress on the effects and underlying mechanisms of evodiamine in digestive system diseases, and its toxicity: a systematic review and meta-analysis. Phytomedicine. 2024;132:155851.","journal-title":"Phytomedicine"},{"key":"1262_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.eng.2024.04.003","volume":"39","author":"Z Ding","year":"2024","unstructured":"Ding Z, Wang X, Zhang Y, Liu J, Wan L, Li T, et al. Altered iron-mediated metabolic homeostasis governs the efficacy and toxicity of Tripterygium glycosides tablets against rheumatoid arthritis. Engineering. 2024;39:166\u201379.","journal-title":"Engineering"},{"key":"1262_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122839","volume":"352","author":"AC Medeot","year":"2024","unstructured":"Medeot AC, Boaglio AC, Salas G, Maidagan PM, Miszczuk GS, Barosso IR, et al. Tauroursodeoxycholate prevents estradiol 17\u03b2-d-glucuronide-induced cholestasis and endocytosis of canalicular transporters by switching off pro-cholestatic signaling pathways. Life Sci. 2024;352:122839.","journal-title":"Life Sci"},{"key":"1262_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156102","volume":"135","author":"JQ Zhao","year":"2024","unstructured":"Zhao JQ, Sun Y, Yang LL, Long J, Jiang Y, Li HJ. New finding based on Comparative Toxicogenomics Database: Hepatic YY1 mediates drug-induced liver injury. Phytomedicine. 2024;135:156102.","journal-title":"Phytomedicine"},{"key":"1262_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jhep.2024.09.037","volume":"82","author":"ED Dixon","year":"2024","unstructured":"Dixon ED, Claudel T, Nardo AD, Riva A, Fuchs CD, Mlitz V, et al. Inhibition of ATGL alleviates MASH via impaired PPAR\u03b1 signalling that favours hydrophilic bile acid composition in mice. J Hepatol. 2024;82:658.","journal-title":"J Hepatol"},{"issue":"1","key":"1262_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","volume":"82","author":"CD Fuchs","year":"2025","unstructured":"Fuchs CD, Simbrunner B, Baumgartner M, Campbell C, Reiberger T, Trauner M. Bile acid metabolism and signalling in liver disease. J Hepatol. 2025;82(1):134\u201353.","journal-title":"J Hepatol"},{"key":"1262_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.mam.2017.06.001","volume":"56","author":"M Li","year":"2017","unstructured":"Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects Med. 2017;56:45\u201353.","journal-title":"Mol Aspects Med"},{"issue":"4","key":"1262_CR29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/HEP.0000000000000611","volume":"79","author":"Y Zhuang","year":"2024","unstructured":"Zhuang Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, Huang H, Wang Y, et al. Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1. Hepatology. 2024;79(4):752\u201367.","journal-title":"Hepatology"},{"issue":"9","key":"1262_CR30","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.7150\/thno.96174","volume":"14","author":"M Li","year":"2024","unstructured":"Li M, Tang Q, Liao C, Wang Z, Zhang S, Liang Q, et al. Extracellular vesicles from apoptotic BMSCs ameliorate osteoporosis via transporting regenerative signals. Theranostics. 2024;14(9):3583\u2013602.","journal-title":"Theranostics"},{"issue":"3","key":"1262_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41418-024-01260-2","volume":"31","author":"TL Saunders","year":"2024","unstructured":"Saunders TL, Windley SP, Gervinskas G, Balka KR, Rowe C, Lane R, et al. Exposure of the inner mitochondrial membrane triggers apoptotic mitophagy. Cell Death Differ. 2024;31(3):335\u201347.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1262_CR32","doi-asserted-by":"publisher","first-page":"1949095","DOI":"10.1080\/19490976.2021.1949095","volume":"13","author":"J Xiang","year":"2021","unstructured":"Xiang J, Zhang Z, Xie H, Zhang C, Bai Y, Cao H, et al. Effect of different bile acids on the intestine through enterohepatic circulation based on FXR. Gut Microbes. 2021;13(1):1949095.","journal-title":"Gut Microbes"},{"issue":"8","key":"1262_CR33","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","volume":"33","author":"BL Clifford","year":"2021","unstructured":"Clifford BL, Sedgeman LR, Williams KJ, Morand P, Cheng A, Jarrett KE, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021;33(8):1671-1684.e1674.","journal-title":"Cell Metab"},{"key":"1262_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cells13151296","author":"GM Gallucci","year":"2024","unstructured":"Gallucci GM, Hayes CM, Boyer JL, Barbier O, Assis DN, Ghonem NS. Ppar-mediated bile acid glucuronidation: therapeutic targets for the treatment of cholestatic liver diseases. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13151296.","journal-title":"Cells"},{"issue":"4","key":"1262_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenw\u00e4lder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022;77(4):1136\u201360.","journal-title":"J Hepatol"},{"issue":"11","key":"1262_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","volume":"21","author":"CL Hsu","year":"2023","unstructured":"Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol. 2023;21(11):719\u201333.","journal-title":"Nat Rev Microbiol"},{"issue":"38","key":"1262_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404274","volume":"11","author":"J Shen","year":"2024","unstructured":"Shen J, Li Z, Liu X, Zheng M, Zhang P, Chen Y, et al. Sensing of liver-derived nicotinamide by intestinal group 2 innate lymphoid cells links liver cirrhosis and ulcerative colitis susceptibility. Adv Sci. 2024;11(38):e2404274.","journal-title":"Adv Sci"},{"issue":"7","key":"1262_CR38","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s42255-024-01063-2","volume":"6","author":"Y Fu","year":"2024","unstructured":"Fu Y, Mackowiak B, Lin YH, Maccioni L, Lehner T, Pan H, et al. Coordinated action of a gut-liver pathway drives alcohol detoxification and consumption. Nat Metab. 2024;6(7):1380\u201396.","journal-title":"Nat Metab"},{"issue":"9","key":"1262_CR39","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00210-023-02455-z","volume":"396","author":"F Safari","year":"2023","unstructured":"Safari F, Sharifi M, Talebi A, Mehranfard N, Ghasemi M. Alleviation of cholestatic liver injury and intestinal permeability by lubiprostone treatment in bile duct ligated rats: role of intestinal FXR and tight junction proteins claudin-1, claudin-2, and occludin. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(9):2009\u201322.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"28","key":"1262_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400206","volume":"11","author":"J Liang","year":"2024","unstructured":"Liang J, Dai W, Liu C, Wen Y, Chen C, Xu Y, et al. Gingerenone A attenuates ulcerative colitis via targeting IL-17RA to inhibit inflammation and restore intestinal barrier function. Adv Sci (Weinh). 2024;11(28):e2400206.","journal-title":"Adv Sci (Weinh)"},{"issue":"9","key":"1262_CR41","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.7150\/thno.81571","volume":"13","author":"W Zhou","year":"2023","unstructured":"Zhou W, Zhang H, Huang L, Sun C, Yue Y, Cao X, et al. Disulfiram with Cu(2+) alleviates dextran sulfate sodium-induced ulcerative colitis in mice. Theranostics. 2023;13(9):2879\u201395.","journal-title":"Theranostics"},{"key":"1262_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jare.2024.03.026","volume":"69","author":"S Li","year":"2025","unstructured":"Li S, Zhuge A, Chen H, Han S, Shen J, Wang K, et al. Sedanolide alleviates DSS-induced colitis by modulating the intestinal FXR-SMPD3 pathway in mice. J Adv Res. 2025;69:413\u201326.","journal-title":"J Adv Res"},{"issue":"7","key":"1262_CR43","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/ecco-jcc\/jjae024","volume":"18","author":"PJ Koelink","year":"2024","unstructured":"Koelink PJ, G\u00f3mez-Mellado VE, Duijst S, van Roest M, Meisner S, Ho-Mok KS, et al. The phospholipid flippase ATP8B1 is involved in the pathogenesis of ulcerative colitis via establishment of intestinal barrier function. J Crohns Colitis. 2024;18(7):1134\u201346.","journal-title":"J Crohns Colitis"},{"key":"1262_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.702890","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Y, Liu Y, Xu J, Liu Y. Gut-liver axis: liver sinusoidal endothelial cells function as the hepatic barrier in colitis-induced liver injury. Front Cell Dev Biol. 2021;9:702890.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1262_CR45","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1038\/s41467-023-38840-8","volume":"14","author":"W Gui","year":"2023","unstructured":"Gui W, Hole MJ, Molinaro A, Edlund K, J\u00f8rgensen KK, Su H, et al. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis. Nat Commun. 2023;14(1):3304.","journal-title":"Nat Commun"},{"issue":"1","key":"1262_CR46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13020-023-00853-2","volume":"18","author":"L Li","year":"2023","unstructured":"Li L, Yang L, Yang L, He C, He Y, Chen L, et al. Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine. Chin Med. 2023;18(1):146.","journal-title":"Chin Med"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01262-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01262-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01262-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:02:16Z","timestamp":1763683336000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-025-01262-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01262-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7515324\/v1","asserted-by":"object"}]},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}